Takeda strengthens patient offering in India via availability of Vedolizumab (Kynteles®). Takeda introduces innovative gastrointestinal portfolio for patients with Inflammatory Bowel Diseases (IBD)and Ulcerative Colitis and Crohn’s Disease. Kynteles®is likely
Koki Sato to lead Takeda’s business in India, ensuring patient access to highly innovative medicines.He is seasoned biopharmaceutical leader with over 17 years of experience across geographies. Delhi, 01April, 2020:
